24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Licensing
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
23:19
Sharvit’s Shin Bet nomination in jeopardy—read the full Trump critique that sparked backlash
17:22
Rippling alleges ‘spy’ was paid in Deel espionage case
14:12
Entrée Capital appoints former CRO of monday.com Yoni Osherov as General Partner
14:00
Israel’s tech ecosystem defies uncertainty with $2.13 billion raised in Q1
More stories
Buzz
Most popular
Daily
Weekly
1
Intel CEO Lip-Bu Tan: "We will remain focused" on cutting costs and complexity
2
Deel and Rippling corporate espionage case takes a turn as accused ‘spy’ agrees to cooperate
3
"The incredible acquisition of Wiz by Google is a testament to the strength of the Israeli ecosystem"
4
The top 10 Israeli startups to watch out for in 2025
5
“Quantum Computing is a cross industry revolution, and we want to be part of it”
More news
Licensing
4 stories about Licensing
Israeli roads off-limits to Tesla Cybertruck due to licensing issues
18.07.24
|
Tomer Hadar
Ministry of Transportation holds back approval over bulletproof concerns
“Licensing practices are tilting the market in favor of certain providers against others”
07.05.22
|
James Spiro
Francisco Mingorance, Executive General at CISPE, explains how cloud monopolies are affecting licensing agreements online
Israel to Set Up Fast Track for Licensing Fintech Projects
19.08.19
|
Meir Orbach
According to the Israeli Ministry of Finance, there are currently 2,000 different entities awaiting licensing, many of which are fintech and blockchain companies that need to make only slight adjustments to comply with current regulations
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026